Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib

Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.

Patrick Harrington^{1

2}, Katie J Doores³, Jamie Saunders^#¹, Marc de Lord^#⁴, Chandan Saha¹, Thomas Lechmere³, Hataf Khan³, Ho Pui Jeff Lam¹, Amy O' Reilly¹, Claire Woodley¹, Susan Asirvatham¹, Richard Dillon^{1

5}, Natalia Curto-Garcia¹, Jennifer O' Sullivan¹, Shahram Kordasti^{1

2}, Kavita Raj¹, Michael H Malim³, Deepti Radia¹, Donal McLornan^{1

2}, Claire Harrison^{1

2}, Hugues de Lavallade^{6

7}

¹ Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
² School of Cancer and Pharmaceutical Science, King's College London, London, UK.
³ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
⁴ Department of Population Health Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
⁵ Department of Medicine and Molecular Genetics, King's College London, London, UK.
⁶ Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK. h.delavallade@nhs.net.
⁷ School of Cancer and Pharmaceutical Science, King's College London, London, UK. h.delavallade@nhs.net.

^# Contributed equally.

No abstract available

Publication types